Spots Global Cancer Trial Database for carcinoma
Every month we try and update this database with for carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Phase II Neoadjuvant Trial of a Continuous Infusion of Paclitaxel Plus Cisplatin Followed by Chest Radiotherapy for Patients With Stage III Non-Small Cell Lung Cancer | NCT00001499 | Carcinoma, Non-... Lung Neoplasms | paclitaxel cisplatin chest radiother... | - | National Institutes of Health Clinical Center (CC) | |
| The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study | NCT02793128 | Carcinoma, Tran... Transitional Ce... | UGN-101 instill... | 18 Years - | UroGen Pharma Ltd. | |
| Seocalcitol Versus Placebo in the Adjuvant Treatment of Hepatocellular Carcinoma | NCT00051545 | Liver Neoplasms | Seocalcitol | 18 Years - 75 Years | LEO Pharma | |
| Phase I Trial of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin Plus Early Postoperative Intraperitoneal Paclitaxel and 5-FU for Peritoneal Carcinomatosis | NCT00001569 | Carcinoma Peritoneal Neop... | Cisplatin Paclitaxel 5-FU | - | National Institutes of Health Clinical Center (CC) | |
| A Study of Ixabepilone Before Surgery for High-Risk Localized Prostate Cancer | NCT00672009 | Prostatic Disea... Genital Neoplas... Urogenital Neop... Genital Disease... Adenocarcinoma Prostatic Neopl... Neoplasms, Glan... Carcinoma | Ixabepilone | - | Cedars-Sinai Medical Center | |
| Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours. | NCT01398306 | Carcinoma Carcinoma, Rena... Neuroendocrine ... Carcinoid Tumor Pancreatic Isle... | Blood sampling ... | 18 Years - | University Medical Center Groningen | |
| A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) | NCT04222972 | RET-fusion Non ... Lung Neoplasm Carcinoma, Non-... Respiratory Tra... Thoracic Neopla... Neoplasms by Si... Neoplasms Lung Diseases Respiratory Tra... Carcinoma, Bron... Bronchial Disea... Head and Neck N... Adenocarcinoma Carcinoma Neoplasms by Hi... Neoplasms, Germ... Neoplasms, Nerv... | Pralsetinib Carboplatin Cisplatin Pemetrexed Pembrolizumab Gemcitabine Paclitaxel Nab-Paclitaxel | 18 Years - | Hoffmann-La Roche | |
| Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2) | NCT03915184 | Multiple Myelom... | zevor-cel | 18 Years - 79 Years | CARsgen Therapeutics Co., Ltd. | |
| Study Of AG-013736 In Patients With 131I-Refractory Thyroid Cancer | NCT00389441 | Thyroid Neoplas... | AG-013736 | 18 Years - | Pfizer | |
| A Study of the Safety and Tolerance of CAN04 in Combination With FOLFIRINOX in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma | NCT04990037 | Metastatic Panc... | CAN04 FOLFIRINOX | 18 Years - | Cantargia AB | |
| uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto | NCT05874921 | Urothelial Carc... Urothelial Carc... Urothelial Carc... Urothelial Carc... Urothelial Canc... Urothelial Carc... Carcinoma, Tran... Transitional Ce... | Jelmyto (mitomy... | 18 Years - | UroGen Pharma Ltd. | |
| Sym004 Versus TAS-102 in Patients With mCRC | NCT03717038 | Metastatic Colo... Colorectal Canc... Carcinoma | Sym004 TAS-102 | 18 Years - | Symphogen A/S | |
| Itraconazole in Advanced Ovarian Cancer | NCT05591560 | Ovarian Carcino... | Itraconazole ca... Placebo | 18 Years - 65 Years | Tanta University | |
| Study Of AG-013736 (Axitinib) In Patients With Advanced Solid Tumors | NCT00447005 | Carcinoma | Axitinib (AG-01... | 20 Years - 75 Years | Pfizer | |
| Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy | NCT03703297 | Small Cell Lung... | Durvalumab Tremelimumab Placebo | 18 Years - 130 Years | AstraZeneca | |
| A Randomized Phase III Trial Comparing Folfirinox to Gemcitabine in Locally Advanced Pancreatic Carcinoma | NCT02539537 | Pancreatic Canc... Carcinoma | Gemcitabine Folinic Acid 5-Fluoro-uracil Oxaliplatin Irinotecan L-folinic | 18 Years - | UNICANCER | |
| Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors | NCT01081808 | Neoplasms Tumors Solid Tumors Metastatic Canc... | EGFRBi-armed au... | 18 Years - | Roger Williams Medical Center | |
| A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Solid Tumors | NCT05860374 | Sarcoma Carcinoma Breast Cancer Pancreatic Canc... Colorectal Canc... Gastric Cancer Liver Cancer Lung Cancer Gynecologic Can... | Recombinant onc... | 18 Years - 75 Years | Shanghai Yunying Medical Technology | |
| Effectiveness and Safety Study of TACE Plus Oral Sorafenib for Unresectable HCC | NCT00576056 | Carcinoma, Hepa... | Sorafenib TACE | 18 Years - 100 Years | University of Pittsburgh | |
| SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry | NCT03452774 | Cancer, Metasta... Cancer Cancer of Pancr... Cancer of Liver Cancer of Stoma... Cancer Liver Cancer of Rectu... Cancer of Kidne... Cancer of Esoph... Cancer of Cervi... Cancer of Colon Cancer of Laryn... Cancer, Lung Cancer, Breast Cancer, Advance... Cancer Prostate Cancer of Neck Cancer of Skin Neuroendocrine ... Carcinoma Mismatch Repair... BRCA Gene Rearr... Non Hodgkin Lym... Leukemia Non Small Cell ... Cholangiocarcin... Glioblastoma Central Nervous... Melanoma Urothelial Carc... Bladder Cancer Ovarian Cancer Endometrial Can... Testicular Canc... Breast Cancer COVID Myelofibrosis Myeloproliferat... Myeloproliferat... Follicular Lymp... Mantle Cell Lym... Marginal Zone L... Myelodysplastic... | Clinical Trial ... | - | Massive Bio, Inc. | |
| Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck | NCT03708224 | Cancer Carcinoma Squamous Cell C... Head and Neck C... | Atezolizumab Tocilizumab Tiragolumab | 18 Years - | University of California, San Francisco | |
| A Study of Yttrium-90 Radioactive Resin Microspheres to Treat Colorectal Adenocarcinoma Metastatic to the Liver | NCT01098422 | Colorectal Neop... Liver Neoplasms | Yttrium-90 Radi... | 18 Years - | University of California, San Diego | |
| A Phase 1/2 Study of BA3071 as Monotherapy and in Combination With a PD-1 Blocking Antibody in Patients With Advanced Solid Tumors | NCT05180799 | Solid Tumor, Ad... NSCLC Urothelial Carc... Gastric Cancer Small Cell Lung... Hepatocellular ... Cervical Carcin... Melanoma Renal Cell Carc... Carcinoma | BA3071 Nivolumab Pembrolizumab | 18 Years - | BioAtla, Inc. | |
| Study of M200 (Volociximab) in Patients With Metastatic Renal Cell Carcinoma (RCC) | NCT00100685 | Renal Cell Carc... Metastases | Volociximab (an... | 18 Years - | Abbott | |
| Imgatuzumab in Patients With Advanced Cutaneous Squamous Cell Carcinoma | NCT04985825 | Cutaneous Squam... | Imgatuzumab | 18 Years - | Centessa Pharmaceuticals plc | |
| Registry Platform Ovarian and Endometrial Cancer | NCT05129969 | Ovarian Cancer Endometrial Can... Ovary Neoplasm Endometrial Neo... Carcinoma, Ovar... Carcinoma Neoplasm, Ovari... | Physician's cho... | 18 Years - | iOMEDICO AG | |
| Study of M200 (Volociximab) in Patients With Metastatic Renal Cell Carcinoma (RCC) | NCT00100685 | Renal Cell Carc... Metastases | Volociximab (an... | 18 Years - | Abbott | |
| Imgatuzumab in Patients With Advanced Cutaneous Squamous Cell Carcinoma | NCT04985825 | Cutaneous Squam... | Imgatuzumab | 18 Years - | Centessa Pharmaceuticals plc | |
| Maintenance Treatment for Ovarian Carcinoma in Remission by an Antiangiogenic Treatment Strategy | NCT01175772 | Ovarian Carcino... | Cytophosphan, C... | 20 Years - 80 Years | HaEmek Medical Center, Israel | |
| What Benefit of a Full Analysis of Exome? Routine Care Study in Patients With Solid Tumors | NCT02840604 | Carcinoma | 18 Years - 99 Years | Centre Georges Francois Leclerc | ||
| A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer | NCT00781911 | Carcinoma Neuroendocrine ... | Cixutumumab depot octreotid... | 18 Years - | Eli Lilly and Company | |
| A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer | NCT02507544 | Carcinoma Advanced Cancer | TRX-818 capsule... | 18 Years - | TaiRx, Inc. | |
| Randomized Phase 2 Trial of Pre-chemotherapy Leukine vs. Leukine-Dexamethasone in Combination With Gemzar & 5-FU in Patients With Metastatic Renal Cell Carcinoma | NCT00176280 | Renal Cell Carc... | Leukine Dexamethasone | 18 Years - | University of Kentucky | |
| Analysis of Brain Metastasis in Patients With Lung Cancer | NCT00071344 | Carcinoma, Non-... | - | National Institutes of Health Clinical Center (CC) | ||
| Sym004 Versus Futuximab or Modotuximab in Patients With mCRC | NCT03549338 | Metastatic Colo... Colorectal Canc... Carcinoma | Sym004 Futuximab Modotuximab | 18 Years - | Symphogen A/S | |
| A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer | NCT02259582 | Nonsquamous Non... | Pemetrexed Carboplatin demcizumab | 21 Years - | Mereo BioPharma | |
| Capecitabine and Lenvatinib With External Radiation in Rectal Adenocarcinoma | NCT02935309 | Rectal Cancer Rectal Adenocar... | Lenvatinib Capecitabine External Radiat... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the Bladder | NCT02202772 | Urothelial Carc... | Cabazitaxel Gemcitabine Cisplatin | 18 Years - | Columbia University | |
| Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma. | NCT01035229 | Carcinoma | Everolimus Everolimus Plac... Best Supportive... | 18 Years - | Novartis | |
| A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer | NCT00887536 | Breast Cancer | bevacizumab docetaxel doxorubicin cyclophosphamid... pegfilgrastim | 18 Years - 70 Years | NSABP Foundation Inc | |
| Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer | NCT04614103 | Metastatic Non ... | LN-145 LN-145 | 18 Years - 70 Years | Iovance Biotherapeutics, Inc. | |
| Vaccination With Flt3L, Radiation, and Poly-ICLC | NCT03789097 | Non-Hodgkin's L... Metastatic Brea... Head and Neck S... | Pembrolizumab Flt3L Radiation Poly ICLC | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Study of Oral Darinaparsin in Patients With Advanced Solid Tumors | NCT01139346 | Advanced Solid ... | darinaparsin | 18 Years - | Alaunos Therapeutics | |
| Trial of Motexafin Gadolinium and Pemetrexed (Alimta®) for Second Line Treatment in Patients With Non-Small Cell Lung Cancer | NCT00365183 | Non-Small Cell ... | Motexafin gadol... | 18 Years - | Pharmacyclics LLC. | |
| ARQ 501 in Combination With Docetaxel in Patients With Cancer | NCT00099190 | Carcinoma | ARQ 501 | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| Trial of Motexafin Gadolinium and Pemetrexed (Alimta®) for Second Line Treatment in Patients With Non-Small Cell Lung Cancer | NCT00365183 | Non-Small Cell ... | Motexafin gadol... | 18 Years - | Pharmacyclics LLC. | |
| A Trial of C-met Kinase Inhibitor HS-10241 in Subjects With Advanced Solid Tumours | NCT02977364 | Carcinoma Solid Tumor, Ad... | HS-10241 | 18 Years - 65 Years | Jiangsu Hansoh Pharmaceutical Co., Ltd. | |
| Evaluation of 68-GaNOTA-Anti-HER2 VHH1 Uptake in Brain Metastasis of Cancer Patients | NCT03331601 | Carcinoma Receptor, ErbB-... | 68GaNOTA-Anti-H... | 18 Years - | Universitair Ziekenhuis Brussel | |
| Comparing Efficacy of Sorafenib Versus Sorafenib in Combination With Low-dose FP in Patients With Advanced HCC | NCT01214343 | Advanced Hepato... Carcinoma Carcinoma, Hepa... Liver Neoplasms Neoplasms | Sorafenib with ... Sorafenib | 20 Years - | Ministry of Health, Labour and Welfare, Japan | |
| Efficacy and Safety Study of TOOKAD® Soluble for Localised Prostate Cancer Compared to Active Surveillance. | NCT01310894 | Prostate Cancer | TOOKAD® Soluble | 18 Years - | Steba Biotech S.A. | |
| Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer | NCT02412670 | High Grade Uppe... | Methotrexate Vinblastine Doxorubicin Cisplatin Gemcitabine Carboplatin Pegfilgrastim Nephroureterect... | 18 Years - | Eastern Cooperative Oncology Group | |
| Efficacy and Safety Study of TOOKAD® Soluble for Localised Prostate Cancer Compared to Active Surveillance. | NCT01310894 | Prostate Cancer | TOOKAD® Soluble | 18 Years - | Steba Biotech S.A. | |
| A Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin in Patients With Advanced Solid Tumors | NCT01664000 | Solid Tumors | thioureidobutyr... | 18 Years - | Cellceutix Corporation | |
| Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers | NCT06001658 | Pancreatic Canc... | Gemcitabine Cisplatin Pembrolizumab | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6 | NCT03058289 | Breast Cancer Head and Neck C... Squamous Cell C... Lymphoma Pancreatic Canc... Liver Cancer Colon Cancer Lung Cancer Bile Duct Cance... Chordoma of Sac... Sarcoma | INT230-6 anti-PD-1 antib... anti-CTLA-4 ant... | 18 Years - | Intensity Therapeutics, Inc. | |
| Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) | NCT04379596 | Gastric Cancer | Fluorouracil (5... Capecitabine Durvalumab Oxaliplatin Trastuzumab Trastuzumab der... Cisplatin Pembrolizumab Volrustomig Rilvegostomig | 18 Years - 130 Years | AstraZeneca | |
| MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC | NCT02592577 | Non-Small Cell ... Carcinoma | Autologous Gene... | 18 Years - | Adaptimmune | |
| Registry Platform Ovarian and Endometrial Cancer | NCT05129969 | Ovarian Cancer Endometrial Can... Ovary Neoplasm Endometrial Neo... Carcinoma, Ovar... Carcinoma Neoplasm, Ovari... | Physician's cho... | 18 Years - | iOMEDICO AG | |
| Therapeutic Effect Of Luteolin Natural Extract Versus Its Nanoparticles On Tongue Squamous Cell Carcinoma Cell Line | NCT03288298 | Tongue Neoplasm... Carcinoma | luteolin nano-luteolin | - | Cairo University | |
| Level of Expression and Prognostic Value of CXCL4, CXCL4L1 and CXCR3 in Renal Cell Carcinoma | NCT01339975 | Carcinoma Carcinoma Renal... Kidney Neoplasm... Kidney Diseases Chemokines | Biological samp... Biological samp... | 18 Years - | University Hospital, Bordeaux | |
| Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer | NCT05014776 | Pancreatic Canc... | Tadalafil Pembrolizumab Ipilimumab CRS-207 | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Cisplatin + Radiation in SCCHN and Correlation With Oxidative Stress Markers | NCT02994069 | Carcinoma, Squa... Head and Neck C... | Cisplatin XRT | 18 Years - | University of Kentucky | |
| KTP vs CO2 Laser for the Treatment of Laryngeal Carcinoma | NCT02672904 | Laryngeal Neopl... | CO2 laser KTP laser | 18 Years - | Kaplan Medical Center | |
| Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC) | NCT03769467 | Nasopharyngeal ... Nasopharyngeal ... Epstein-Barr Vi... Epstein-Barr Vi... Epstein-Barr Vi... | tabelecleucel pembrolizumab | 12 Years - | Atara Biotherapeutics | |
| A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer | NCT02507544 | Carcinoma Advanced Cancer | TRX-818 capsule... | 18 Years - | TaiRx, Inc. | |
| Comprehensive Digital Archive of Cancer Imaging-Radiation Oncology( CHAVI-RO ) | NCT04249895 | All Cancer | - | Tata Medical Center | ||
| Circulating Tumor DNA Detection in Surveillance of Surgical Lung Cancer Patients | NCT02696525 | Carcinoma Non-small-cell ... Lung Neoplasms | 18 Years - 80 Years | Peking University People's Hospital | ||
| Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer | NCT02440425 | Ovarian Cancer | Pembrolizumab Paclitaxel | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Expanded Access to Ensartinib for Participants With ALK+ NSCLC | NCT04146571 | Non-Small Cell ... ALK Gene Rearra... | Ensartinib | 18 Years - | Xcovery Holdings, Inc. | |
| Trial of Chemotherapy in Ovarian, Fallopian Tube and Peritoneal Carcinoma | NCT01519869 | Primary Periton... Ovarian Carcino... Fallopian Tube ... | neoadjuvant che... | 18 Years - | University of Kentucky | |
| Safety and Efficacy Clinical Study of SNS-595 in Patients With Advanced Small Cell Lung Cancer | NCT00298896 | Carcinoma, Smal... Small Cell Lung... | SNS-595 | 18 Years - | Sunesis Pharmaceuticals | |
| Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot be Removed by Surgery | NCT02072356 | Adult Primary H... Advanced Adult ... Localized Unres... Recurrent Adult... | yttrium Y 90 gl... laboratory biom... TheraSphere | 8 Years - | Ohio State University Comprehensive Cancer Center | |
| Trial of Liposomal Doxorubicin (Doxil) and Weekly Docetaxel (Taxotere) | NCT00183742 | Cancer Carcinoma | liposomal doxor... | 18 Years - | University of Southern California | |
| Safety/Efficacy Study of Imprime PGG With Cetuximab in Patients With Recurrent/Progressive Colorectal Carcinoma | NCT00545545 | Recurrent Color... Progressive Col... | Safety and effi... Safety and effi... | 18 Years - 75 Years | HiberCell, Inc. | |
| A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer | NCT06317311 | Carcinoma | Dostarlimab Carboplatin Paclitaxel | 18 Years - | GlaxoSmithKline | |
| A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer | NCT05361174 | Unresectable Me... Metastatic Mela... Stage III Non-s... Stage IV Non-sm... | IOV-4001 | 18 Years - | Iovance Biotherapeutics, Inc. | |
| Voice Prosthesis Made in Porous Titanium After Total Laryngectomy or Pharyngolaryngectomy | NCT00396617 | Pharyngeal Neop... Laryngeal Neopl... Carcinoma | prothesis voice total laryngect... | 18 Years - | University Hospital, Strasbourg, France | |
| SIR-Spheres Study to Calculate the Radiation-Absorbed Dose of 99mTc-MAA | NCT05848947 | Carcinoma Carcinoma, Hepa... Liver Neoplasm | 99mTc-Macro Alb... | 18 Years - | Sirtex Medical | |
| Open-label Multicenter Phase 1 Study of TBI 302 as Second-Line Therapy in Patients With Hepatocellular Carcinoma | NCT03908840 | Hepatocellular ... | TBI 302 | 18 Years - | Therapure Biopharma Inc | |
| Efficacy Study of Chemoradiotherapy With or Without Paclitaxel in Squamous-cell Anal Carcinoma Patients | NCT02526953 | Anus Neoplasms Carcinoma, Squa... Anus Diseases Neoplasms Neoplasms, Squa... Carcinoma | Paclitaxel Capecitabine Capecitabine Mitomycins Mitomycins Radiotherapy | 18 Years - 70 Years | Blokhin's Russian Cancer Research Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
